Drug Trial Radar · NCT01101412
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies
Last checked: Nov 20, 2026Latest source record: Feb 15, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Apr 12, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Antimicrobial solution comprising trimethoprim-sulfamethoxazole, edetate calcium disodium, and ethanol may help prevent blockages and infections from forming in patients with central venous access catheters or peripheral venous catheters. PURPOSE: This randomized trial is studying an antimicrobial solution or saline solution in maintaining catheter patency and preventing catheter-related blood infections in patients with malignancies.
Conditions
- Chronic Myeloproliferative Disorders
- Infection
- Leukemia
- Lymphoma
- Lymphoproliferative Disorder
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms
- Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Edetate Calcium DisodiumDrug
Given through CVC or PVC.
EthanolDrug
Given through CVC or PVC
Trimethoprim-sulfamethoxazoleDrug
Given through CVC or PVC
Hypertonic SalineOther
Given through CVC or PVC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of occlusion as defined by the inability to infuse or withdraw 3 cc of saline from the catheterTime frame: 60 days
- Time to development of a catheter-related bloodstream infections during the period of lock therapy administrationTime frame: 60 days
- Adverse eventsTime frame: 60 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.